News

HYpharm's innovative preventive agent HY-133 has reached the first clinical trial phase. HY-133 is specifically effective against the bacterial pathogen Staphylococcus aureus including multi-resistant

According to estimates, 4.95 million deaths worldwide in 2019 were directly or indirectly attributable to infections with resistant bacteria. The rising number of resistant bacterial pathogens, also

Most antibiotics used in human medicine originate from natural products derived from bacteria and other microbes. Novel microorganisms are therefore a promising source of new active compounds—also for

In a large-scale systematic review, researchers from an international consortium analysed more than 25,000 publications from the last 20 years. They examined the circumstances under which contact

Many bacteria produce substances to gain an advantage over competitors in their highly competitive natural environment. Researchers at the University Hospital Bonn (UKB), the University of Bonn and

The Presbyterian Hospital in Agogo, Ghana, recorded zero deaths among women during or after childbirth last year. This is a major medical success after 499 fatalities in 2020. The hospital management

Leukaemia is the most common cancer in children. Cancer treatment severely weakens the children's immune system and they can easily develop opportunistic infections. One of the most common causes of

Over 12 million people worldwide suffer from a chronic infection with the hepatitis D virus. This most severe viral liver disease is associated with a high risk of dying from liver cirrhosis and liver

While tuberculosis (TB) has become relatively rare in Germany and other industrialised nations, around ten million people contract the bacterial infection every year, especially in resource-poorer

New active substances for the treatment of resistant bacteria are needed more urgently than ever – yet only few candidates make the leap from research to clinical application. To facilitate precisely